Email updates

Keep up to date with the latest news and content from BMC Neurology and BioMed Central.

Open Access Study protocol

The effect of static scanning and mobility training on mobility in people with hemianopia after stroke: A randomized controlled trial comparing standardized versus non-standardized treatment protocols

Stacey George1*, Allison Hayes2, Celia Chen3 and Maria Crotty1

Author Affiliations

1 Flinders University, Division of Rehabilitation, Aged Care and Allied Health, Repatriation General Hospital, Daw Park, South Australia, 5043, Australia

2 Neuro Vision Technology, PO Box 141, Torrensville, South Australia, 5031, Australia

3 Department of Ophthalmology, Flinders Medical Centre and Flinders University, Flinders Drive, Bedford Park, South Australia, 5042 Australia

For all author emails, please log on.

BMC Neurology 2011, 11:87  doi:10.1186/1471-2377-11-87

Published: 19 July 2011

Abstract

Background

Visual loss following stroke impacts significantly on activities of daily living and is an independent risk factor for becoming dependent. Routinely, allied health clinicians provide training for visual field loss, mainly with eye movement based therapy. The effectiveness of the compensatory approach to rehabilitation remains inconclusive largely due to difficulty in validating functional outcome with the varied type and dosage of therapy received by an individual patient. This study aims to determine which treatment is more effective, a standardized approach or individualized therapy in patients with homonymous hemianopia post stroke.

Methods/Design

This study is a double-blind randomized controlled, multicenter trial. A standardised scanning rehabilitation program (Neuro Vision Technology (NVT) program) of 7 weeks at 3 times per week, is compared to individualized therapy recommended by clinicians.

Discussion

The results of the trial will provide information that could potentially inform the allocation of resources in visual rehabilitation post stroke.

Trial Registration

Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12610000494033